Tigecycline Pharmacokinetic and Pharmacodynamic Profile in Patients with Chronic Obstructive Pulmonary Disease Exacerbation

• Main Authors: Maria Kipourou (Author), Olga Begou (Author), Katerina Manika (Author), Georgios Ismailos (Author), Paschalina Kontou (Author), Georgia Pitsiou (Author), Helen Gika (Author), Ioannis Kioumis (Author)
• Format: Book
• Published: MDPI AG, 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Background: We aimed to evaluate the pharmacokinetic profile of tigecycline in plasma and its penetration to sputum in moderately ill patients with an infectious acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods: Eleven patients hospitalized with acute respiratory failure due to an acute COPD exacerbation with clinical evidence of an infectious cause received tigecycline 50 mg twice daily after an initial loading dose of 100 mg. Blood and sputum samples were collected at steady state after dose seven. Results: In plasma, mean C_max pl was 975.95 ± 490.36 ng/mL and mean C_min pl was 214.48 ±140.62 ng/mL. In sputum, mean C_max sp was 641.91 ± 253.07 ng/mL and mean C_min sp was 308.06 ± 61.7 ng/mL. In plasma, mean AUC _0-12 pl was 3765.89 ± 1862.23 ng*h/mL, while in sputum mean AUC _{0-12 sp} was 4023.27 ± 793.37 ng*h/mL. The mean penetration ratio for the 10/11 patients was 1.65 ± 1.35. The mean Free AUC_{0-24 pl}/MIC ratio for <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> was 25.10 ± 12.42 and 6.02 ± 2.97, respectively. Conclusions: Our findings support the clinical effectiveness of tigecycline against commonly causative bacteria in COPD exacerbations and highlight its sufficient lung penetration in pulmonary infections of moderate severity.

Item Description

10.3390/antibiotics12020307
2079-6382